Mesoblast, a stem cell biotechnology company, is on fire right now. Investors are rallying behind Mesoblasts COVID-19 treatment (Remestemcel-l). MESO’s phase I trial resulted in an 83% (10 out of 12) survival rate. Remestemcel-L is now under Phase II trials with 300 COVID-19 patients. A pleasing survival rate could see MSB erupt like a volcano.
While COVID-19 is moving Mesoblast into the spotlight, investors must understand that success is not new for MESO. Take away the COVID-19 hype. You are then have nine drug candidates ranging from chronic lower back pain, to cardiovascular and pediatric diseases.
disallowedlink/2020/06/02/gilead-produces-mixed-covid-19-trial-results-investors-now-look-to-mesoblast/
Cell Therapy News/Articles, page-3122
-
- There are more pages in this discussion • 15,127 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.39 |
Change
0.040(2.96%) |
Mkt cap ! $1.541B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.40 | $1.37 | $1.289M | 932.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 51116 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 312081 | 23 |
View Market Depth
| Last trade - 10.09am 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |